Abstract: The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.
Type:
Grant
Filed:
February 14, 2022
Date of Patent:
April 25, 2023
Assignee:
ALNYLAM PHARMACEUTICALS, INC.
Inventors:
Martin Maier, Muthusamy Jayaraman, Akin Akinc, Shigeo Matsuda, Pachamuthu Kandasamy, Kallanthottathil G. Rajeev, Muthiah Manoharan
Abstract: The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.
Type:
Grant
Filed:
February 14, 2022
Date of Patent:
April 25, 2023
Assignee:
ALNYLAM PHARMACEUTICALS, INC.
Inventors:
Martin Maier, Muthusamy Jayaraman, Akin Akinc, Shigeo Matsuda, Pachamuthu Kandasamy, Kallanthottathil G. Rajeev, Muthiah Manoharan
Abstract: The invention relates to methods of inhibiting the expression of a PCSK9 gene in a subject, as well as therapeutic and prophylactic methods for treating subjects having a lipid disorder, such as a hyperlipidemia using RNAi agents, e.g., double-stranded RNAi agents, targeting the PCSK9 gene.
Type:
Application
Filed:
March 31, 2022
Publication date:
April 6, 2023
Applicants:
Alnylam Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc.
Abstract: The present invention relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting the KISS1 gene. The invention also relates to methods of using such RNAi agents to inhibit expression of a KISS1 gene and to methods of preventing and treating a deficiency in glycemic control, e.g., type 2 diabetes mellitus (T2DM).
Abstract: The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.
Type:
Grant
Filed:
February 14, 2022
Date of Patent:
March 28, 2023
Assignee:
ALNYLAM PHARMACEUTICALS, INC.
Inventors:
Martin Maier, Muthusamy Jayaraman, Akin Akinc, Shigeo Matsuda, Pachamuthu Kandasamy, Kallanthottathil G. Rajeev, Muthiah Manoharan
Abstract: The present invention relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting the Angiopoietin-like 3 (ANGPTL3) gene. The invention also relates to methods of using such RNAi agents to inhibit expression of an ANGPTL3 gene and to methods of preventing and treating an ANGPTL3-associated disorder, e.g., a disorder of lipid metabolism, such as hyperlipidemia or hypertriglyceridemia.
Type:
Grant
Filed:
March 8, 2022
Date of Patent:
March 28, 2023
Assignee:
Alnylam Pharmaceuticals, Inc.
Inventors:
Lucas D. BonDurant, Mark K. Schlegel, Jeffrey Zuber, Lauren Blair Woods, Tyler Chickering
Abstract: The present invention relates to a chirally-modified dsRNA agent capable of inhibiting the expression of a target gene. The sense and antisense strands of chirally-modified dsRNA agent independently or in combination comprises one or more site specific-site specific/position specific, chirally-modified internucleotide linkages.
Type:
Grant
Filed:
December 21, 2018
Date of Patent:
March 7, 2023
Assignee:
Alnylam Pharmaceuticals, Inc.
Inventors:
Muthiah Manoharan, Nate Taneja, Hartmut Ingo Jahns, Shigeo Matsuda, Klaus Charisse, Guo He, Jayaprakash K. Nair, Christopher Brown, Mark K. Schlegel, Vasant Jadhav, Martin Maier
Abstract: The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.
Type:
Grant
Filed:
February 14, 2022
Date of Patent:
February 28, 2023
Assignee:
ALNYLAM PHARMACEUTICALS, INC.
Inventors:
Martin Maier, Muthusamy Jayaraman, Akin Akinc, Shigeo Matsuda, Pachamuthu Kandasamy, Kallanthottathil G. Rajeev, Muthiah Manoharan
Abstract: The disclosure relates to double-stranded ribonucleic acid (dsRNA) agents and compositions targeting the ATXN3 gene, as well as methods of inhibiting expression of an APP gene and methods of treating subjects having an ATXN3-associated disease or disorder, such as SCA3, using such dsRNA agents and compositions.
Type:
Application
Filed:
November 20, 2020
Publication date:
February 23, 2023
Applicant:
ALNYLAM PHARMACEUTICALS, INC.
Inventors:
ADAM CASTORENO, ELANE FISHILEVICH, JASON A. GILBERT, CHARALAMBOS KAITTANIS, JAMES D. MCININCH, STUART MILSTEIN, MARK K. SCHLEGEL
Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a mutant Epidermal Growth Factor Receptor (EGFR), and methods of using the dsRNA to inhibit expression of mutant EGFR.
Type:
Application
Filed:
April 29, 2022
Publication date:
February 23, 2023
Applicants:
ALNYLAM PHARMACEUTICALS, INC., LUDWIG INSTITUTE FOR CANCER RESEARCH LTD.
Inventors:
DINAH SAH, PAMELA TAN, WEBSTER CAVENEE, FRANK FURNARI, MARIA DEL MAR INDA PEREZ, RUDY BONAVIA
Abstract: The disclosure is directed to dual variable domain immunoglobulin double-stranded RNA conjugates that are advantageous for inhibition of target gene expression, as well as compositions suitable for therapeutic use. The dual variable domain immunoglobulin comprises a first variable domain that binds to a binding target, and a second variable domain that comprises a reactive residue, where the linker is covalently conjugated to the reactive residue. The dsRNA is linked to the linker and is capable of inhibiting the expression of the target gene by RNA interference. The disclosure also provides pharmaceutical compositions comprising these conjugate and methods of inhibiting the expression of a target gene by administering these conjugates, e.g., for the treatment of various disease conditions.
Type:
Application
Filed:
June 18, 2020
Publication date:
February 16, 2023
Applicants:
Alnylam Pharmaceuticals, Inc., THE SCRIPPS RESEARCH INSTITUTE
Inventors:
Alexander V. KEL'IN, Alex R. NANNA, Christopher RADER, Christopher THEILE, Justin PIERSON, Kevin FITZGERALD, Zhi Xiang VOO
Abstract: The disclosure relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the DNAJB 1-PRKAC A fusion gene, and methods of using such dsRNA compositions to alter (e.g., inhibit) expression of DNAJB 1-PRKAC A fusion.
Type:
Application
Filed:
October 30, 2020
Publication date:
February 9, 2023
Applicant:
ALNYLAM PHARMACEUTICALS, INC.
Inventors:
LEILA NOETZLI, HO-CHOU TU, PATRICK HASLETT, JAMES MCININCH
Abstract: Provided is a method of treating cancer cells localized in the lung by administering to such patients a therapeutically effective amount of a liposomal annamycin formulation (L-Ann).
Type:
Application
Filed:
November 23, 2020
Publication date:
January 26, 2023
Applicant:
ALNYLAM PHARMACEUTICALS, INC.
Inventors:
Jayaprakash K. NAIR, Juan C. SALINAS, John Frederick BRIONES, Mark K. SCHLEGEL, Shigeo MATSUDA, Alexander V. KEL'IN, Ligang ZHANG, Martin A. MAIER
Abstract: The present invention relates, in general to agents that modulate the pharmacological activity of siRNAs. In addition, the invention relates generally to methods and systems for use in assessing the efficacy and safety of a pharmaceutical composition for use in the treatment or prophylaxis of a disease.
Type:
Application
Filed:
January 25, 2022
Publication date:
January 26, 2023
Applicant:
ALNYLAM PHARMACEUTICALS, INC.
Inventors:
Ivan ZLATEV, Adam CASTORENO, Martin MAIER, Vasant JADHAV, Jae KIM, Pushkal GARG
Abstract: The present invention provides RNAi agents, e.g., double stranded RNAi agents, that target the transthyretin (TTR) gene and methods of using such RNAi agents for treating or preventing TTR-associated diseases.
Type:
Application
Filed:
July 9, 2021
Publication date:
January 12, 2023
Applicant:
Alnylam Pharmaceuticals, Inc.
Inventors:
Kallanthottathil G. Rajeev, Tracy Zimmermann, Muthiah Manoharan, Martin A. Maier, Satyanarayana Kuchimanchi, Klaus Charisse
Abstract: One aspect of the present invention relates to double-stranded RNA (dsRNA) agent capable of inhibiting the expression of a target gene. The sense strand of the dsRNA agent comprises at least one thermally destabilizing nucleotide, and at least one said thermally destabilizing nucleotide occurring at a site opposite to the seed region (positions 2-8) of the antisense strand; and the antisense strand of the dsRNA agent comprises. at least two modified nucleotides that provide the nucleotide a steric bulk that is less than or equal to the steric bulk of a 2?-OMe modification, wherein said modified nucleotides are separated by 11 nucleotides in length. Other aspects of the invention relates to pharmaceutical compositions comprising these dsRNA agents suitable for therapeutic use, and methods of inhibiting the expression of a target gene by administering these dsRNA agents, e.g., for the treatment of various disease conditions.
Type:
Grant
Filed:
June 23, 2022
Date of Patent:
January 10, 2023
Assignee:
Alnylam Pharmaceuticals, Inc.
Inventors:
Martin Maier, Don Foster, Stuart Milstein, Satya Kuchimanchi, Vasant Jadhav, Kallanthottathil Rajeev, Muthiah Manoharan, Rubina Parmar
Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the ANGPTL3 gene, as well as methods of inhibiting expression of ANGPTL3 and methods of treating subjects having a disorder of lipid metabolism, such as hyperlipidemia or hypertriglyceridemia, using such dsRNA compositions.
Type:
Grant
Filed:
April 6, 2022
Date of Patent:
December 13, 2022
Assignee:
Alnylam Pharmaceuticals, Inc.
Inventors:
Brian Bettencourt, William Querbes, Kevin Fitzgerald, Maria Frank-Kamenetsky, Stuart Milstein, Svetlana Shulga Morskaya
Abstract: The disclosure relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the UGT1a1 gene, and methods of using such dsRNA compositions to alter (e.g., inhibit) expression of UGT1a1.
Abstract: One aspect of the present invention relates to double-stranded RNA (dsRNA) agent capable of inhibiting the expression of a target gene. Other aspects of the invention relate to pharmaceutical compositions comprising these dsRNA molecules suitable for therapeutic use, and methods of inhibiting the expression of a target gene by administering these dsRNA molecules, e.g., for the treatment of various disease conditions.